JPH0812588A - Composition - Google Patents
CompositionInfo
- Publication number
- JPH0812588A JPH0812588A JP6170426A JP17042694A JPH0812588A JP H0812588 A JPH0812588 A JP H0812588A JP 6170426 A JP6170426 A JP 6170426A JP 17042694 A JP17042694 A JP 17042694A JP H0812588 A JPH0812588 A JP H0812588A
- Authority
- JP
- Japan
- Prior art keywords
- mycelium
- solvent
- composition according
- composition
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、すぐれた薬理、健康効
果を有する組成物に関するものであり、更に詳細にはコ
ルジセプス・ミリタリス菌由来の医薬品タイプ及び/又
は飲食品タイプの組成物に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a composition having excellent pharmacological and health effects, and more particularly to a pharmaceutical type composition and / or a food / beverage type composition derived from Cordyceps militaris.
【0002】[0002]
【従来の技術】冬虫夏草は、子のう菌類(Ascomy
cota)、核菌綱(Pyrenomycetes)、
麦角菌目(Clavicipitales)、麦角菌科
(Clavicipitaceae又はHypocre
acea)、冬虫夏草属(Cordyceps)に属
し、完全時代と不完全時代とを有する微生物である。BACKGROUND OF THE INVENTION Cordyceps is an ascomycete fungus.
cota), Pyrenomycetes,
Clavicipitales, Clavicipitaceae or Hypocre
acea), which belongs to the genus Cordyceps and has a complete era and an incomplete era.
【0003】冬虫夏草は、その子実体が、不老長寿の妙
薬として、あるいはまた滋養強壮の妙薬として、古来よ
り珍重されてきた。このようにして従来より漢方薬とし
て重用されてきた冬虫夏草は、通常、子実体を粉末化
し、これを服用するものである。The caterpillar of Cordyceps sinensis has been prized since ancient times for its fruiting body as a medicinal agent for longevity and as a nutritional tonic. In this way, the Cordyceps sinensis, which has been conventionally heavily used as a herbal medicine, is usually obtained by pulverizing the fruiting bodies and taking them.
【0004】これに対して本発明は、特定の冬虫夏草を
培養し、得られた培養菌糸体を溶媒で抽出したものであ
るが、このような溶媒抽出物にすぐれた強心作用及び鎮
咳作用があることは従来全く知られていない。On the other hand, the present invention is one in which a specific Cordyceps sinensis is cultivated and the obtained cultured mycelium is extracted with a solvent. Such a solvent extract has excellent cardiotonic action and antitussive action. This has never been known.
【0005】[0005]
【発明が解決しようとする課題】本発明は、強心作用及
び鎮咳作用にすぐれた薬剤又はこれらの作用を有する飲
食品を新たに開発する目的で、しかも安全性重視の面か
ら長時間投与にも充分耐えるよう天然物由来の物質を開
発する目的でなされたものである。DISCLOSURE OF THE INVENTION The present invention is intended for the purpose of newly developing a drug excellent in cardiotonic action and antitussive action or foods and drinks having these actions, and also for long-term administration from the viewpoint of safety. It was made for the purpose of developing a substance derived from a natural product so as to sufficiently endure it.
【0006】[0006]
【課題を解決するための手段】上記課題を解決するため
に各方面から検討した結果、漢方薬に着目し、冬虫夏
草、特にコルジセプス・ミリタリスに着目し、そして更
に研究の末、その培養菌糸体、しかもその溶媒抽出物に
すぐれた強心作用及び鎮咳作用があることを発見し、こ
の新知見に基づき更に研究の結果、遂に本発明を完成し
た。以下、本発明を詳述する。[Means for Solving the Problems] As a result of examining from various aspects to solve the above problems, attention is focused on Chinese herbs, Cordyceps militaris, especially Cordyceps militaryalis, and after further research, its mycelium, and It was discovered that the solvent extract had excellent cardiotonic action and antitussive action, and as a result of further research based on this new finding, the present invention was finally completed. Hereinafter, the present invention will be described in detail.
【0007】本発明を実施するには、冬虫夏草に属する
コルジセプス・ミリタリスの菌糸体を培養し、培養菌糸
体を取得する必要がある。本発明においては、コルジセ
プス・ミリタリスに属する微生物(以下、本菌というこ
ともある)が使用でき、例えば、コルジセプス・ミリタ
リス MF−20005(Cordyceps mil
itaris MF−20005)は有用であり、本菌
株を工業技術院生命工学工業技術研究所にFERM P
−14398として寄託した。In order to carry out the present invention, it is necessary to cultivate the mycelium of Cordyceps militaris belonging to the Cordyceps sinensis and to obtain the cultured mycelium. In the present invention, a microorganism belonging to Cordyceps militaryis (hereinafter sometimes referred to as the present bacterium) can be used, and for example, Cordyceps militaryis MF-20005 (Cordyceps mil) can be used.
Itaris MF-20005) is useful, and this strain was transferred to the Institute of Biotechnology, Institute of Industrial Science and Technology, FERM P
Deposited as -14398.
【0008】本発明においては、コルジセプス・ミリタ
リスの菌糸体を培養する。[0008] In the present invention, the mycelium of Cordyceps militaris is cultured.
【0009】培養は麦芽エキス、イーストエキストラク
ト、ペプトン、バレイシヨ煮出汁、ブドウ糖、ビタミン
類、アミノ酸類、核酸類、蛋白質類、及び必要あれば昆
虫等寄主の成分を加えた培地を用い、液体ないし固体培
養によって充分に増殖せしめる。Cultivation is carried out using a medium containing malt extract, yeast extract, peptone, broccoli broth, glucose, vitamins, amino acids, nucleic acids, proteins and, if necessary, host components such as insects, which are liquid or liquid. Sufficiently grow by solid culture.
【0010】大量培養の場合は、液体培養、しかも通気
攪拌培養を行うのが好ましく、pH4〜7、培養温度1
5〜32℃、好ましくは20〜30℃、50〜500r
pm、好ましくは100〜300rpm程度にゆっくり
攪拌しながら3日〜10日培養するのが好ましい。In the case of large-scale culturing, it is preferable to carry out liquid culturing and aeration stirring culturing, pH 4 to 7, culturing temperature 1
5 to 32 ° C, preferably 20 to 30 ° C, 50 to 500r
It is preferable to carry out the culture for 3 to 10 days while slowly stirring at pm, preferably about 100 to 300 rpm.
【0011】培養終了後、培養液は濾過し、菌糸体と培
養濾液に分ける。菌糸体は溶媒で抽出する。溶媒として
は、水のほか有機溶媒が使用される。有機溶媒として
は、メタノール、エタノール、プロパノール、ブタノー
ル等のアルコール;メチルエーテル、エチルエーテル、
プロピルエーテル、メチルエチルエーテル、メチルプロ
ピルエーテル等のエーテル;アセトン、エチルメチルケ
トン、メチルプロピルケトン、ブチルメチルケトン等の
ケトンが適宜使用され、これらの混合溶媒、水との混合
溶媒も使用可能である。溶媒の量に格別の限定はない
が、乾燥菌体1g当り好ましくは1ml〜1Lとするの
が好適である。After completion of the culture, the culture solution is filtered to separate into mycelium and culture filtrate. The mycelium is extracted with a solvent. As the solvent, water and an organic solvent are used. As the organic solvent, alcohols such as methanol, ethanol, propanol, butanol; methyl ether, ethyl ether,
Ethers such as propyl ether, methyl ethyl ether, and methyl propyl ether; ketones such as acetone, ethyl methyl ketone, methyl propyl ketone, and butyl methyl ketone are appropriately used, and a mixed solvent thereof and a mixed solvent with water can also be used. . Although the amount of the solvent is not particularly limited, it is preferably 1 ml to 1 L per 1 g of dry cells.
【0012】水抽出の場合、培養菌糸体を85〜140
℃、好ましくは90〜125℃の高温条件下で抽出を行
う。この場合、培養菌糸体に水を加え、必要あれば菌糸
体を粉砕した後、所望により攪拌しながら高温条件下で
抽出を行う。通常は熱水を使用して抽出するが、更に高
温での抽出を行う場合には、オートクレーブ抽出を行え
ばよい。In the case of water extraction, the cultured mycelium is added to 85-140.
Extraction is performed under high temperature conditions of 90 ° C., preferably 90 to 125 ° C. In this case, water is added to the cultured mycelium, the mycelium is crushed if necessary, and then extraction is carried out under high temperature conditions with stirring if desired. Usually, hot water is used for extraction, but when extraction is performed at a higher temperature, autoclave extraction may be performed.
【0013】得られた溶媒抽出物は、抽出残渣を除去し
た後、液状部をそのまま、あるいはその処理物を本発明
組成物の有効成分として使用する。処理物としては、液
状部の濃縮物、ペースト状物、乾燥物及び/又は液状部
の希釈物が広く包含される。また必要あれば、抽出残渣
を除去することなく、溶媒抽出物をそのまま使用するこ
と及びその処理物を使用することも可能である。The solvent extract thus obtained is used as the active ingredient of the composition of the present invention after the extraction residue is removed, and then the liquid part is used as it is or the treated product is used. The processed product broadly includes a concentrate in the liquid part, a paste, a dried product and / or a diluent in the liquid part. If necessary, it is also possible to use the solvent extract as it is or to use the treated product without removing the extraction residue.
【0014】本菌糸体の培養濾液或いは溶媒抽出物(処
理物も包含する)は、後記する実施例からも明らかなよ
うに、強心作用及び鎮咳作用ないし気管支の収縮抑制作
用を有するので、本発明に係る組成物は、これらの作用
を利用した飲食品、特定保健用飲食品、健康飲料、健康
食品、栄養食品その他各種タイプの飲食品として用いる
ことができるほか、強心剤又は鎮咳剤等医薬品としても
用いることができる。The culture filtrate or the solvent extract (including the treated product) of the mycelium has a cardiotonic action, an antitussive action and a bronchoconstriction inhibiting action, as will be apparent from the examples described below. The composition according to can be used as food and drink utilizing these actions, food and drink for specified health use, health drink, health food, nutritional food and other various types of food and drink, and also used as a medicine such as cardiotonic agent or antitussive. be able to.
【0015】飲食品タイプの組成物として使用する場合
には、本有効成分である培養濾液及び/又は溶媒抽出物
(その処理物)をそのまま、使用したり、他の食品ない
し食品成分と併用したりして適宜常法にしたがって使用
できる。本有効成分を用いる本発明に係る組成物は、固
体状(粉末、顆粒状その他)、ペースト状、液状ないし
懸濁状のいずれでもよいが、甘味料、酸味料、ビタミン
剤その他ドリンク剤製造に常用される各種成分を用い
て、健康ドリンクに製剤化すると好適である。When used as a food and drink type composition, the culture filtrate and / or the solvent extract (the processed product), which is the present active ingredient, can be used as it is or in combination with other foods or food ingredients. Or, it can be used according to an ordinary method. The composition according to the present invention using the present active ingredient may be in a solid form (powder, granules, etc.), paste form, liquid form or suspension form, but for the production of sweeteners, acidulants, vitamins and other drinks. It is preferable to formulate a health drink using various commonly used ingredients.
【0016】医薬品タイプの組成物として使用する場
合、本有効成分は、種々の形態で投与される。その投与
形態としては例えば錠剤、カプセル剤、顆粒剤、散剤、
シロップ剤等による経口投与をあげることができる。こ
れらの各種製剤は、常法に従って主薬に賦形剤、結合
剤、崩壊剤、滑沢剤、矯味矯臭剤、溶解補助剤、懸濁
剤、コーティング剤などの医薬の製剤技術分野において
通常使用しうる既知の補助剤を用いて製剤化することが
できる。その使用量は症状、年令、体重、投与方法およ
び剤形等によって異なるが、通常は、成人に対して1回
約0.1mg乃至1,000mgを投与することができ
る。When used as a pharmaceutical type composition, the active ingredient is administered in various forms. Examples of the dosage form include tablets, capsules, granules, powders,
Oral administration such as syrup may be mentioned. These various preparations are commonly used in the pharmaceutical preparation technical field such as excipients, binders, disintegrants, lubricants, flavoring agents, solubilizing agents, suspending agents, coating agents, and the like, in accordance with the usual methods for the main drug. It can be formulated using known adjuvants. Although the amount used varies depending on symptoms, age, body weight, administration method, dosage form, etc., usually, about 0.1 mg to 1,000 mg can be administered once to an adult.
【0017】本発明に係る有効成分は、天然起源であり
しかも永年にわたって漢方薬として使用されていたもの
を起源とするため、毒性は全くないか又は極めて低く、
卓越した安全性を示し、ラットに対して1日当り500
mg経口投与したが急性毒性は全く認められなかった。
したがって飲食品タイプの組成物として使用する場合
は、予防用、保健用、飲食品として使用する場合のいず
れにおいても有効成分の使用量に格別の限定はないし、
医薬として使用する場合でも、患者に応じて上記範囲内
で適宜使用すればよい。また、本有効成分は多量に服用
しても格別の急性毒性を示さないので、必要あれば上記
範囲よりも多量に使用しても差し支えない。Since the active ingredient according to the present invention has a natural origin and has been used as a herbal medicine for many years, it has no or very low toxicity.
Shows excellent safety, 500 per day for rats
Oral oral administration (mg) was not observed, but no acute toxicity was observed.
Therefore, when used as a food-drink type composition, there is no particular limitation on the amount of the active ingredient used for prevention, health care, or when used as a food or drink,
Even when it is used as a medicine, it may be appropriately used within the above range depending on the patient. Further, since the present active ingredient does not exhibit remarkable acute toxicity even if it is taken in a large amount, it may be used in a larger amount than the above range if necessary.
【0018】以下、本発明の製造例及び実施例について
詳述する。The production examples and examples of the present invention will be described in detail below.
【0019】[0019]
【製造例1】M20Y2培地(100ml中の組成:麦
芽エキス(Oxoid)2g、酵母エキス(Difc
o)0.2g;pH5.5)を500ml容三角フラス
コに100mlずつ分注し、オートクレーブで121
℃、15分間滅菌した。[Production Example 1] M20Y2 medium (composition in 100 ml: malt extract (Oxoid) 2 g, yeast extract (Difc)
o) 0.2 g; pH 5.5) was dispensed into a 500 ml Erlenmeyer flask in 100 ml aliquots and placed in an autoclave for 121
Sterilized at 15 ° C for 15 minutes.
【0020】これらの滅菌培地に、Cordyceps
militaris MF−20005(FERM
P−14398)のM20Y2寒天スラント培養菌糸体
を1白金耳接種し、25℃、180rpmの条件で5日
間旋回振とう培養を行い、それぞれ培養物を得た。培養
物を遠心分離し、分離した菌糸体と濾液とをそれぞれ凍
結乾燥した。These sterilized media were added to Cordyceps
militaris MF-20005 (FERM
(P-14398) M20Y2 agar slant culture mycelium was inoculated with 1 platinum loop and cultivated with orbital shaking at 25 ° C. and 180 rpm for 5 days to obtain a culture. The culture was centrifuged and the separated mycelium and filtrate were freeze-dried.
【0021】濾液の乾燥物を試料(1)とした。菌糸体
は、乾燥物を2分し、1つは、メタノール20mlを添
加攪拌後1夜冷蔵下で静置し、この濾液を試料(2)と
した。残りの1つは精製水40mlに懸濁し、冷却管を
付けて90℃で2時間加熱抽出後、濾過し、濾液を凍結
乾燥し試料(3)とした。濾過により残った菌糸体は、
さらに精製水40mlに懸濁し121℃、15分間加熱
抽出し、濾液を凍結乾燥し試料(4)とした。(図1)The dried product of the filtrate was used as sample (1). For the mycelium, the dried product was divided into 2 minutes, and one of them was added and stirred with 20 ml of methanol and left standing overnight under refrigeration, and this filtrate was used as a sample (2). The remaining one was suspended in 40 ml of purified water, heated with a cooling tube at 90 ° C. for 2 hours for extraction, filtered, and the filtrate was freeze-dried to obtain a sample (3). The mycelium remaining after filtration is
Further, it was suspended in 40 ml of purified water, heated and extracted at 121 ° C. for 15 minutes, and the filtrate was freeze-dried to obtain a sample (4). (Fig. 1)
【0022】[0022]
【実施例1】製造例1において製造した冬虫夏草菌糸体
の培養濾液又は当該菌糸体の溶媒抽出物について、SD
ラットから摘出した心臓、気管支を用いて、角尾らの方
法(Kurokawa M.and Tsunoo
A., J.Physiol.,407,135−15
3,1988;Tsunoo A.et al.,
J.Physiol.,433,163−181,19
91)に従い、その作用を試験し、有効性を確認した。[Example 1] SD of the culture filtrate of Cordyceps mycelium or the solvent extract of the mycelium produced in Production Example 1
Using the heart and bronchus isolated from the rat, the method of Kuroo et al. (Kurokawa M. and Tsunooo) was used.
A. , J. Physiol. , 407 , 135-15
3, 1988; Tsunoo A .; et al. ,
J. Physiol. , 433 , 163-181, 19
According to 91), its action was tested and its effectiveness was confirmed.
【0023】(1)心筋標本 培養濾液及び溶媒抽出物を適用して雄SDラット右心房
に対する心筋の収縮力及び収縮間隔時間の相対値をそれ
ぞれ求めた。雄SDラット(380〜450g)からペ
ースメーカー機能を保持したまま右心房を摘出した。右
心房標本は容積0.8mlの横型かん流槽に固定し、収
縮力を等尺性に記録した。かん流液は95%酸素、5%
炭酸ガスで平衡させたクレブス液、または以下の組成を
持ち、通気させた塩溶液(塩化ナトリウム140mM、
塩化カリウム5mM、塩化カルシウム2.6mM、塩化
マグネシウム1.3mM、グルコース10mM、HEP
ES5mM)を使用した。かん流液は36〜37℃に保
ち、流速は3〜4ml/分とした。(1) Myocardial Specimens The relative values of the contractile force of the myocardium and the contraction interval time with respect to the right atrium of the male SD rat were determined by applying the culture filtrate and the solvent extract. The right atrium was extracted from a male SD rat (380 to 450 g) while maintaining the pacemaker function. The right atrium sample was fixed in a horizontal perfusion tank with a volume of 0.8 ml, and the contraction force was recorded isometrically. Perfusate is 95% oxygen, 5%
Krebs solution equilibrated with carbon dioxide, or a salt solution (sodium chloride 140 mM, aerated with the following composition)
Potassium chloride 5 mM, calcium chloride 2.6 mM, magnesium chloride 1.3 mM, glucose 10 mM, HEP
ES5mM) was used. The perfusate was kept at 36-37 ° C and the flow rate was 3-4 ml / min.
【0024】その結果、培養濾液及び溶媒抽出物(10
0μg/ml)は右心房筋の自動能による収縮の張力
を、対照の10〜15%増加させた。自動能による収縮
の間隔時間には著名な効果を及ぼさなかった。As a result, the culture filtrate and the solvent extract (10
0 μg / ml) increased the tension of contraction by the autonomic capacity of the right atrial muscle by 10 to 15% of the control. It did not have a prominent effect on the time interval between contractions by the automatic function.
【0025】(2)気管支標本 培養濾液及び溶媒抽出物を適用して、雄SDラット気管
支の電気刺激による収縮に対する同抽出物の有効性、及
び、カリウムによる収縮に対する同抽出物の有効性を測
定した。雄SDラットから気管支を摘出し、螺旋状標本
を作製した。標本は上記と同じ条件でかん流層に固定し
た。刺激用50mM塩化カリウム液も同様に作製した。
電気刺激は、かん流槽内の白金線を通して30秒間隔で
行った。(2) Bronchial specimen By applying the culture filtrate and the solvent extract, the effectiveness of the extract on contraction of male SD rat bronchus by electrical stimulation and the effectiveness of the extract on contraction by potassium were measured. did. A bronchus was extracted from a male SD rat to prepare a spiral specimen. The sample was fixed in the perfusion layer under the same conditions as above. A 50 mM potassium chloride solution for stimulation was similarly prepared.
The electrical stimulation was performed at intervals of 30 seconds through a platinum wire in the perfusion tank.
【0026】その結果、培養濾液以外の全ての溶媒抽出
物は、電気刺激による気管支の一過性収縮を抑制した
(図2)。50mMカリウムによる持続性収縮に対し培
養濾液及び溶媒抽出物は弛緩効果を示した(下記表
1)。この場合の弛緩率は、50mMカリウム収縮値を
100%とし、それに対する弛緩値を%で示してある。As a result, all solvent extracts other than the culture filtrate suppressed the transient contraction of the bronchi due to electrical stimulation (FIG. 2). The culture filtrate and the solvent extract showed a relaxing effect on the persistent contraction by 50 mM potassium (Table 1 below). In the relaxation rate in this case, the contraction value of 50 mM potassium is 100%, and the relaxation value is shown in%.
【0027】[0027]
【表1】 [Table 1]
【0028】(1)〜(2)の結果から、本発明の溶媒
抽出物はおだやかな心筋収縮力増強効果を有し、また培
養濾液も含めて気管支の一過性および持続性収縮を抑制
することから気道抵抗の低下をおこし肺換気の効率増加
をもたらす、と考えられる。すなわち、本発明に係る組
成物には、強心剤及び鎮咳剤としての有用性があること
が確認された。From the results of (1) and (2), the solvent extract of the present invention has a mild myocardial contractile force-enhancing effect and also suppresses transient and persistent contraction of the bronchi including the culture filtrate. Therefore, it is considered that the airway resistance is lowered and the efficiency of lung ventilation is increased. That is, it was confirmed that the composition according to the present invention has utility as a cardiotonic agent and an antitussive agent.
【0029】[0029]
【実施例2】製造例1で得たメタノール抽出物粉末10
0g、糖類150g、蜂蜜15g、アスコルビン酸1
g、クエン酸0.5g、香料適量に水を加えて1Kgと
し、これを95℃で20分間殺菌し、100mlずつ無
菌的にビンに充填して、飲食品タイプの健康ドリンクを
製造した。Example 2 Methanol extract powder 10 obtained in Production Example 1
0 g, sugar 150 g, honey 15 g, ascorbic acid 1
g, 0.5 g of citric acid, and 1 kg of water by adding an appropriate amount of perfume to sterilize the mixture at 95 ° C. for 20 minutes, and aseptically filling 100 ml of each bottle into a food-drink type health drink.
【0030】[0030]
【実施例3】製造例1で得たメタノール抽出物粉末の2
0%水溶液200g、酢酸トコフェロール5g、硝酸チ
アミン10g、ニコチン酸アミド20g、無水力フェイ
ン50g、安息香酸塩及び香料適量に脱イオン水を加え
て30Lとし、殺菌した後30mlずつ無菌的にビンに
充填して、医薬品としての健康ドリンクを製造した。Example 3 2 of the methanol extract powder obtained in Production Example 1
200 g of 0% aqueous solution, 5 g of tocopherol acetate, 10 g of thiamine nitrate, 20 g of nicotinic acid amide, 50 g of anhydrous feine, 50 g of benzoic acid salt and a suitable amount of perfume and deionized water to make 30 L, and after sterilizing, aseptically fill each 30 ml bottle. And manufactured a health drink as a medicine.
【0031】[0031]
【実施例4】 (1)製造例1で製造した物質(2) 50g (2)ラクトース 90g (3)コーンスターチ 29g (4)ステアリン酸マグネシウム 1g (1)、(2)及び(3)(但し17g)を混合し、
(3)(但し7g)から調製したペーストとともに顆粒
化した。得られた顆粒に(3)(但し5g)と(4)を
加えてよく混合し、この混合物を圧縮錠剤機により圧縮
して、1錠あたり有効成分(1)を50mg含有する錠
剤1000個を製造した。Example 4 (1) Material produced in Production Example 1 (2) 50 g (2) Lactose 90 g (3) Corn starch 29 g (4) Magnesium stearate 1 g (1), (2) and (3) (however, 17 g ),
Granulated with the paste prepared from (3) (however, 7 g). To the obtained granules, (3) (however, 5 g) and (4) were added and mixed well, and the mixture was compressed by a compression tableting machine to obtain 1000 tablets each containing 50 mg of the active ingredient (1). Manufactured.
【0032】[0032]
【実施例5】製造例1で製造した物質(2)にかえて同
(4)を使用したほかは、実施例4と同様に処理して、
錠剤を製造した。[Example 5] The same treatment as in Example 4 was carried out except that the substance (2) produced in Production Example 1 was replaced with the same (4),
Tablets were produced.
【0033】[0033]
【発明の効果】本発明によって、天然物由来の安定性が
すぐれしかもおだやかな強心作用及び気管支拡張作用な
いし鎮咳作用を併有する組成物が、天然物由来でありな
がら培養法を採用することにより安定的且つ工業的に供
給される。Industrial Applicability According to the present invention, a composition having excellent stability derived from a natural product and having a gentle cardiotonic action and bronchodilator action or antitussive action is stable by adopting a culturing method even though it is derived from a natural product. And industrially supplied.
【図1】本発明に係る培養濾液及び溶媒抽出物の製造プ
ロセスを示す。1 shows a process for producing a culture filtrate and a solvent extract according to the present invention.
【図2】本発明に係る培養濾液及び溶媒抽出物を適用し
て電気刺激による気管支の一過性収縮に対する効果を示
す。縦軸は対照に対する気管支収縮値の比率を示す。FIG. 2 shows the effect on transient contraction of the bronchus by electrical stimulation by applying the culture filtrate and the solvent extract according to the present invention. The vertical axis represents the ratio of the bronchoconstriction value to the control.
Claims (9)
ceps militaris)の培養菌糸体の培養濾
液及び/又は当該菌糸体の溶媒抽出物を含有してなるこ
とを特徴とする組成物。1. Cordyceps militaryis (Cordy)
composition comprising a culture filtrate of a culture mycelium of Ceps militaris) and / or a solvent extract of the mycelium.
005(Cordyceps militaris M
F−20005)を使用することを特徴とする請求項1
に記載の組成物。2. Corgiceptus militaryis MF-20
005 (Cordyceps militaris M
F-20005) is used.
The composition according to.
テル、ケトンから選ばれる有機溶媒であることを特徴と
する請求項1又は請求項2に記載の組成物。3. The composition according to claim 1 or 2, wherein the solvent is water or an organic solvent selected from alcohols, ethers and ketones.
℃、好ましくは90〜125℃の温度条件下で熱水抽出
してなるものであること、を特徴とする請求項1〜請求
項3のいずれか1項に記載の組成物。4. The water extract gives cultured mycelium in an amount of 85 to 140.
The composition according to any one of claims 1 to 3, which is obtained by hot water extraction under a temperature condition of ° C, preferably 90 to 125 ° C.
抽出してなるものであることを特徴とする請求項1〜請
求項4のいずれか1項に記載の組成物。5. The composition according to any one of claims 1 to 4, wherein the solvent extract is obtained by extracting the cultured mycelium with methanol.
ら抽出残渣を除去した液状部、そ(れら)の濃縮物、ペ
ースト状物、希釈物、及び/又は乾燥物であること、を
特徴とする請求項1〜請求項5のいずれか1項に記載の
組成物。6. The solvent extract is the solvent extract itself, a liquid part obtained by removing the extraction residue therefrom, a concentrate thereof, a paste, a diluent, and / or a dried product. The composition according to any one of claims 1 to 5, characterized in.
品タイプであることを特徴とする請求項1〜請求項6の
いずれか1項に記載の組成物。7. The composition according to claim 1, wherein the composition is a pharmaceutical type and / or a food / beverage type.
を特徴とする請求項7に記載の医薬品タイプの組成物。8. A pharmaceutical type composition according to claim 7, characterized in that said composition is a cardiotonic or antitussive.
徴とする請求項7に記載の飲食品タイプの組成物。9. The food-drink type composition according to claim 7, wherein the composition is a health drink.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6170426A JPH0812588A (en) | 1994-06-30 | 1994-06-30 | Composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6170426A JPH0812588A (en) | 1994-06-30 | 1994-06-30 | Composition |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH0812588A true JPH0812588A (en) | 1996-01-16 |
Family
ID=15904701
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP6170426A Pending JPH0812588A (en) | 1994-06-30 | 1994-06-30 | Composition |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0812588A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR19990046085A (en) * | 1999-03-18 | 1999-06-25 | 김준, 김미란 | Green tea including Paecilomyces japonica and it's preparation method |
KR100799116B1 (en) * | 2006-09-26 | 2008-01-29 | 건국대학교 산학협력단 | A pharmaceutical composition comprising cordycepin for the treatment and prevention of obesity |
CN102499435A (en) * | 2011-11-02 | 2012-06-20 | 深圳市大百汇技术有限公司 | Cordyceps militaris extraction method and cigarette containing cordyceps militaris extract |
CN102835652A (en) * | 2012-09-17 | 2012-12-26 | 江苏神华药业有限公司 | Method for extracting cordyceps hirsutella sinensis mycelia on basis of membrane technology |
CN102835651A (en) * | 2012-09-17 | 2012-12-26 | 江苏神华药业有限公司 | Method for extracting cordyceps cephalosporin mycelia on basis of membrane technology |
WO2019188946A1 (en) * | 2018-03-26 | 2019-10-03 | 小林 文男 | Composition having erythropoietin-inducing activity, and method for producing same |
-
1994
- 1994-06-30 JP JP6170426A patent/JPH0812588A/en active Pending
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR19990046085A (en) * | 1999-03-18 | 1999-06-25 | 김준, 김미란 | Green tea including Paecilomyces japonica and it's preparation method |
KR100799116B1 (en) * | 2006-09-26 | 2008-01-29 | 건국대학교 산학협력단 | A pharmaceutical composition comprising cordycepin for the treatment and prevention of obesity |
CN102499435A (en) * | 2011-11-02 | 2012-06-20 | 深圳市大百汇技术有限公司 | Cordyceps militaris extraction method and cigarette containing cordyceps militaris extract |
CN102835652A (en) * | 2012-09-17 | 2012-12-26 | 江苏神华药业有限公司 | Method for extracting cordyceps hirsutella sinensis mycelia on basis of membrane technology |
CN102835651A (en) * | 2012-09-17 | 2012-12-26 | 江苏神华药业有限公司 | Method for extracting cordyceps cephalosporin mycelia on basis of membrane technology |
WO2019188946A1 (en) * | 2018-03-26 | 2019-10-03 | 小林 文男 | Composition having erythropoietin-inducing activity, and method for producing same |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5948404A (en) | Healthful composition obtained from the hot water extract of Coratceps sinensis mycelia | |
KR102137252B1 (en) | fermented extract for preventing stress alopecia using Lactobacillus plantarum J2K-27, and manufacturing method of it, and cosmetic composition containing fermented extract | |
CN109938332B (en) | Hericium erinaceus health product preparation containing ergothioneine and preparation method thereof | |
CN101020715B (en) | Process of extracting and preparing deer nerve growth factor (DEER NGF) | |
US11407972B1 (en) | Fungal-derived formulations and associated methods | |
JP2001231545A (en) | Separated strain of antrodia camphorata, method for producing the culture product, and product obtained therefrom | |
JPH0812588A (en) | Composition | |
JP2005225802A (en) | New therapeutic agent for hyperlipemia and food | |
WO1998056755A1 (en) | Physiologically active substances tkr2449, process for producing the same, and microorganism | |
JP4000946B2 (en) | New production method of cordyceps and the obtained cordyceps and its use | |
JP2002114701A (en) | Composition for improving lipid metabolism | |
KR100814351B1 (en) | Physiologically active compositions of Basidiomycotina and Araliaceae extracts | |
CN1536069B (en) | Method for large-scale production of catepillar fungus and lucid ganoderma | |
US20230094227A1 (en) | Novel fk506 derivative and composition comprising same for promoting hair growth | |
EP3901157A1 (en) | Novel compound and composition comprising same for stimulating hair growth | |
JP2002272267A (en) | Method for artificially culturing plant worm and extracted composition of isaria japonica and functional food using the same | |
JPH10245341A (en) | Hypoglycemic composition | |
JP3522373B2 (en) | Lactic acid bacteria growth promoter | |
JP2003238437A (en) | Fermented galenical preparation having antioxidative activity | |
US12011497B2 (en) | Compounds, compositions containing same, and use thereof for promoting hair growth | |
JP4931375B2 (en) | Antimuscular fatigue agent and food and drink | |
JP2007112750A (en) | Nitric oxide production inhibitor | |
WO2020203966A1 (en) | Elastase activity inhibitor, elastase activity inhibiting topical agent, and elastase activity inhibiting food and beverage composition | |
JP3720383B2 (en) | Liver function activation improver | |
KR101866850B1 (en) | Anti-inflammatory composition comprising submerged culture of ceriporia lacerata mycellium as an active ingredient |